Global Anti-tumor Drug Market Analysis and Forecast 2024-2030
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
According to APO Research, The global Anti-tumor Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Report Includes
This report presents an overview of global market for Anti-tumor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anti-tumor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-tumor Drug revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anti-tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Anti-tumor Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda and Eli Lilly, etc.
Anti-tumor Drug segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-tumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-tumor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-tumor Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Anti-tumor Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Report Includes
This report presents an overview of global market for Anti-tumor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anti-tumor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-tumor Drug revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anti-tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Anti-tumor Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda and Eli Lilly, etc.
Anti-tumor Drug segment by Company
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
- Cytotoxic Drugs
- Non-cytotoxic Drugs
- Alkylating Agents
- Anti-Metabolism Drugs
- Platinum Antineoplastic Agents
- Anthracycline Antitumor Drugs
- Microtubule Stabilizer
- Endocrine Therapy Drugs
- Immunotherapy Drugs
- Gene Therapy Drugs
- Targeted Antineoplastic Drugs
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-tumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-tumor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-tumor Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Anti-tumor Drug Market by Type
1.2.1 Global Anti-tumor Drug Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Cytotoxic Drugs
1.2.3 Non-cytotoxic Drugs
1.3 Anti-tumor Drug Market by Application
1.3.1 Global Anti-tumor Drug Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Alkylating Agents
1.3.3 Anti-Metabolism Drugs
1.3.4 Platinum Antineoplastic Agents
1.3.5 Anthracycline Antitumor Drugs
1.3.6 Microtubule Stabilizer
1.3.7 Endocrine Therapy Drugs
1.3.8 Immunotherapy Drugs
1.3.9 Gene Therapy Drugs
1.3.10 Targeted Antineoplastic Drugs
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTI-TUMOR DRUG MARKET DYNAMICS
2.1 Anti-tumor Drug Industry Trends
2.2 Anti-tumor Drug Industry Drivers
2.3 Anti-tumor Drug Industry Opportunities and Challenges
2.4 Anti-tumor Drug Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Anti-tumor Drug Market Perspective (2019-2030)
3.2 Global Anti-tumor Drug Growth Trends by Region
3.2.1 Global Anti-tumor Drug Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Anti-tumor Drug Market Size by Region (2019-2024)
3.2.3 Global Anti-tumor Drug Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Anti-tumor Drug Revenue by Players
4.1.1 Global Anti-tumor Drug Revenue by Players (2019-2024)
4.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2019-2024)
4.1.3 Global Anti-tumor Drug Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Anti-tumor Drug Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Anti-tumor Drug Key Players Headquarters & Area Served
4.4 Global Anti-tumor Drug Players, Product Type & Application
4.5 Global Anti-tumor Drug Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Anti-tumor Drug Market CR5 and HHI
4.6.2 Global Top 5 and 10 Anti-tumor Drug Players Market Share by Revenue in 2023
4.6.3 2023 Anti-tumor Drug Tier 1, Tier 2, and Tier
5 ANTI-TUMOR DRUG MARKET SIZE BY TYPE
5.1 Global Anti-tumor Drug Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Anti-tumor Drug Revenue by Type (2019-2030)
5.3 Global Anti-tumor Drug Revenue Market Share by Type (2019-2030)
6 ANTI-TUMOR DRUG MARKET SIZE BY APPLICATION
6.1 Global Anti-tumor Drug Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Anti-tumor Drug Revenue by Application (2019-2030)
6.3 Global Anti-tumor Drug Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.1.4 Roche Anti-tumor Drug Product Portfolio
7.1.5 Roche Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Anti-tumor Drug Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Celgene
7.3.1 Celgene Comapny Information
7.3.2 Celgene Business Overview
7.3.3 Celgene Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.3.4 Celgene Anti-tumor Drug Product Portfolio
7.3.5 Celgene Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Comapny Information
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 Amgen
7.5.1 Amgen Comapny Information
7.5.2 Amgen Business Overview
7.5.3 Amgen Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.5.4 Amgen Anti-tumor Drug Product Portfolio
7.5.5 Amgen Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Comapny Information
7.6.2 Johnson & Johnson Business Overview
7.6.3 Johnson & Johnson Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
7.6.5 Johnson & Johnson Recent Developments
7.7 Pfizer
7.7.1 Pfizer Comapny Information
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer Anti-tumor Drug Product Portfolio
7.7.5 Pfizer Recent Developments
7.8 Takeda
7.8.1 Takeda Comapny Information
7.8.2 Takeda Business Overview
7.8.3 Takeda Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.8.4 Takeda Anti-tumor Drug Product Portfolio
7.8.5 Takeda Recent Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Comapny Information
7.9.2 Eli Lilly Business Overview
7.9.3 Eli Lilly Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
7.9.5 Eli Lilly Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Comapny Information
7.10.2 AstraZeneca Business Overview
7.10.3 AstraZeneca Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
7.10.5 AstraZeneca Recent Developments
7.11 Astellas
7.11.1 Astellas Comapny Information
7.11.2 Astellas Business Overview
7.11.3 Astellas Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.11.4 Astellas Anti-tumor Drug Product Portfolio
7.11.5 Astellas Recent Developments
7.12 Merck & Co
7.12.1 Merck & Co Comapny Information
7.12.2 Merck & Co Business Overview
7.12.3 Merck & Co Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.12.4 Merck & Co Anti-tumor Drug Product Portfolio
7.12.5 Merck & Co Recent Developments
7.13 Sanofi
7.13.1 Sanofi Comapny Information
7.13.2 Sanofi Business Overview
7.13.3 Sanofi Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.13.4 Sanofi Anti-tumor Drug Product Portfolio
7.13.5 Sanofi Recent Developments
7.14 Bayer
7.14.1 Bayer Comapny Information
7.14.2 Bayer Business Overview
7.14.3 Bayer Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.14.4 Bayer Anti-tumor Drug Product Portfolio
7.14.5 Bayer Recent Developments
7.15 Biogen Idec
7.15.1 Biogen Idec Comapny Information
7.15.2 Biogen Idec Business Overview
7.15.3 Biogen Idec Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
7.15.5 Biogen Idec Recent Developments
7.16 Eisai
7.16.1 Eisai Comapny Information
7.16.2 Eisai Business Overview
7.16.3 Eisai Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.16.4 Eisai Anti-tumor Drug Product Portfolio
7.16.5 Eisai Recent Developments
7.17 Teva
7.17.1 Teva Comapny Information
7.17.2 Teva Business Overview
7.17.3 Teva Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.17.4 Teva Anti-tumor Drug Product Portfolio
7.17.5 Teva Recent Developments
7.18 Otsuka
7.18.1 Otsuka Comapny Information
7.18.2 Otsuka Business Overview
7.18.3 Otsuka Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.18.4 Otsuka Anti-tumor Drug Product Portfolio
7.18.5 Otsuka Recent Developments
8 NORTH AMERICA
8.1 North America Anti-tumor Drug Revenue (2019-2030)
8.2 North America Anti-tumor Drug Revenue by Type (2019-2030)
8.2.1 North America Anti-tumor Drug Revenue by Type (2019-2024)
8.2.2 North America Anti-tumor Drug Revenue by Type (2025-2030)
8.3 North America Anti-tumor Drug Revenue Share by Type (2019-2030)
8.4 North America Anti-tumor Drug Revenue by Application (2019-2030)
8.4.1 North America Anti-tumor Drug Revenue by Application (2019-2024)
8.4.2 North America Anti-tumor Drug Revenue by Application (2025-2030)
8.5 North America Anti-tumor Drug Revenue Share by Application (2019-2030)
8.6 North America Anti-tumor Drug Revenue by Country
8.6.1 North America Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Anti-tumor Drug Revenue by Country (2019-2024)
8.6.3 North America Anti-tumor Drug Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Anti-tumor Drug Revenue (2019-2030)
9.2 Europe Anti-tumor Drug Revenue by Type (2019-2030)
9.2.1 Europe Anti-tumor Drug Revenue by Type (2019-2024)
9.2.2 Europe Anti-tumor Drug Revenue by Type (2025-2030)
9.3 Europe Anti-tumor Drug Revenue Share by Type (2019-2030)
9.4 Europe Anti-tumor Drug Revenue by Application (2019-2030)
9.4.1 Europe Anti-tumor Drug Revenue by Application (2019-2024)
9.4.2 Europe Anti-tumor Drug Revenue by Application (2025-2030)
9.5 Europe Anti-tumor Drug Revenue Share by Application (2019-2030)
9.6 Europe Anti-tumor Drug Revenue by Country
9.6.1 Europe Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Anti-tumor Drug Revenue by Country (2019-2024)
9.6.3 Europe Anti-tumor Drug Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Anti-tumor Drug Revenue (2019-2030)
10.2 China Anti-tumor Drug Revenue by Type (2019-2030)
10.2.1 China Anti-tumor Drug Revenue by Type (2019-2024)
10.2.2 China Anti-tumor Drug Revenue by Type (2025-2030)
10.3 China Anti-tumor Drug Revenue Share by Type (2019-2030)
10.4 China Anti-tumor Drug Revenue by Application (2019-2030)
10.4.1 China Anti-tumor Drug Revenue by Application (2019-2024)
10.4.2 China Anti-tumor Drug Revenue by Application (2025-2030)
10.5 China Anti-tumor Drug Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Anti-tumor Drug Revenue (2019-2030)
11.2 Asia Anti-tumor Drug Revenue by Type (2019-2030)
11.2.1 Asia Anti-tumor Drug Revenue by Type (2019-2024)
11.2.2 Asia Anti-tumor Drug Revenue by Type (2025-2030)
11.3 Asia Anti-tumor Drug Revenue Share by Type (2019-2030)
11.4 Asia Anti-tumor Drug Revenue by Application (2019-2030)
11.4.1 Asia Anti-tumor Drug Revenue by Application (2019-2024)
11.4.2 Asia Anti-tumor Drug Revenue by Application (2025-2030)
11.5 Asia Anti-tumor Drug Revenue Share by Application (2019-2030)
11.6 Asia Anti-tumor Drug Revenue by Country
11.6.1 Asia Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Anti-tumor Drug Revenue by Country (2019-2024)
11.6.3 Asia Anti-tumor Drug Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Anti-tumor Drug Revenue (2019-2030)
12.2 MEALA Anti-tumor Drug Revenue by Type (2019-2030)
12.2.1 MEALA Anti-tumor Drug Revenue by Type (2019-2024)
12.2.2 MEALA Anti-tumor Drug Revenue by Type (2025-2030)
12.3 MEALA Anti-tumor Drug Revenue Share by Type (2019-2030)
12.4 MEALA Anti-tumor Drug Revenue by Application (2019-2030)
12.4.1 MEALA Anti-tumor Drug Revenue by Application (2019-2024)
12.4.2 MEALA Anti-tumor Drug Revenue by Application (2025-2030)
12.5 MEALA Anti-tumor Drug Revenue Share by Application (2019-2030)
12.6 MEALA Anti-tumor Drug Revenue by Country
12.6.1 MEALA Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Anti-tumor Drug Revenue by Country (2019-2024)
12.6.3 MEALA Anti-tumor Drug Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Anti-tumor Drug Market by Type
1.2.1 Global Anti-tumor Drug Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Cytotoxic Drugs
1.2.3 Non-cytotoxic Drugs
1.3 Anti-tumor Drug Market by Application
1.3.1 Global Anti-tumor Drug Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Alkylating Agents
1.3.3 Anti-Metabolism Drugs
1.3.4 Platinum Antineoplastic Agents
1.3.5 Anthracycline Antitumor Drugs
1.3.6 Microtubule Stabilizer
1.3.7 Endocrine Therapy Drugs
1.3.8 Immunotherapy Drugs
1.3.9 Gene Therapy Drugs
1.3.10 Targeted Antineoplastic Drugs
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTI-TUMOR DRUG MARKET DYNAMICS
2.1 Anti-tumor Drug Industry Trends
2.2 Anti-tumor Drug Industry Drivers
2.3 Anti-tumor Drug Industry Opportunities and Challenges
2.4 Anti-tumor Drug Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Anti-tumor Drug Market Perspective (2019-2030)
3.2 Global Anti-tumor Drug Growth Trends by Region
3.2.1 Global Anti-tumor Drug Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Anti-tumor Drug Market Size by Region (2019-2024)
3.2.3 Global Anti-tumor Drug Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Anti-tumor Drug Revenue by Players
4.1.1 Global Anti-tumor Drug Revenue by Players (2019-2024)
4.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2019-2024)
4.1.3 Global Anti-tumor Drug Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Anti-tumor Drug Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Anti-tumor Drug Key Players Headquarters & Area Served
4.4 Global Anti-tumor Drug Players, Product Type & Application
4.5 Global Anti-tumor Drug Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Anti-tumor Drug Market CR5 and HHI
4.6.2 Global Top 5 and 10 Anti-tumor Drug Players Market Share by Revenue in 2023
4.6.3 2023 Anti-tumor Drug Tier 1, Tier 2, and Tier
5 ANTI-TUMOR DRUG MARKET SIZE BY TYPE
5.1 Global Anti-tumor Drug Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Anti-tumor Drug Revenue by Type (2019-2030)
5.3 Global Anti-tumor Drug Revenue Market Share by Type (2019-2030)
6 ANTI-TUMOR DRUG MARKET SIZE BY APPLICATION
6.1 Global Anti-tumor Drug Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Anti-tumor Drug Revenue by Application (2019-2030)
6.3 Global Anti-tumor Drug Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.1.4 Roche Anti-tumor Drug Product Portfolio
7.1.5 Roche Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Anti-tumor Drug Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Celgene
7.3.1 Celgene Comapny Information
7.3.2 Celgene Business Overview
7.3.3 Celgene Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.3.4 Celgene Anti-tumor Drug Product Portfolio
7.3.5 Celgene Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Comapny Information
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 Amgen
7.5.1 Amgen Comapny Information
7.5.2 Amgen Business Overview
7.5.3 Amgen Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.5.4 Amgen Anti-tumor Drug Product Portfolio
7.5.5 Amgen Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Comapny Information
7.6.2 Johnson & Johnson Business Overview
7.6.3 Johnson & Johnson Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
7.6.5 Johnson & Johnson Recent Developments
7.7 Pfizer
7.7.1 Pfizer Comapny Information
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer Anti-tumor Drug Product Portfolio
7.7.5 Pfizer Recent Developments
7.8 Takeda
7.8.1 Takeda Comapny Information
7.8.2 Takeda Business Overview
7.8.3 Takeda Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.8.4 Takeda Anti-tumor Drug Product Portfolio
7.8.5 Takeda Recent Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Comapny Information
7.9.2 Eli Lilly Business Overview
7.9.3 Eli Lilly Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
7.9.5 Eli Lilly Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Comapny Information
7.10.2 AstraZeneca Business Overview
7.10.3 AstraZeneca Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
7.10.5 AstraZeneca Recent Developments
7.11 Astellas
7.11.1 Astellas Comapny Information
7.11.2 Astellas Business Overview
7.11.3 Astellas Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.11.4 Astellas Anti-tumor Drug Product Portfolio
7.11.5 Astellas Recent Developments
7.12 Merck & Co
7.12.1 Merck & Co Comapny Information
7.12.2 Merck & Co Business Overview
7.12.3 Merck & Co Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.12.4 Merck & Co Anti-tumor Drug Product Portfolio
7.12.5 Merck & Co Recent Developments
7.13 Sanofi
7.13.1 Sanofi Comapny Information
7.13.2 Sanofi Business Overview
7.13.3 Sanofi Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.13.4 Sanofi Anti-tumor Drug Product Portfolio
7.13.5 Sanofi Recent Developments
7.14 Bayer
7.14.1 Bayer Comapny Information
7.14.2 Bayer Business Overview
7.14.3 Bayer Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.14.4 Bayer Anti-tumor Drug Product Portfolio
7.14.5 Bayer Recent Developments
7.15 Biogen Idec
7.15.1 Biogen Idec Comapny Information
7.15.2 Biogen Idec Business Overview
7.15.3 Biogen Idec Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
7.15.5 Biogen Idec Recent Developments
7.16 Eisai
7.16.1 Eisai Comapny Information
7.16.2 Eisai Business Overview
7.16.3 Eisai Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.16.4 Eisai Anti-tumor Drug Product Portfolio
7.16.5 Eisai Recent Developments
7.17 Teva
7.17.1 Teva Comapny Information
7.17.2 Teva Business Overview
7.17.3 Teva Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.17.4 Teva Anti-tumor Drug Product Portfolio
7.17.5 Teva Recent Developments
7.18 Otsuka
7.18.1 Otsuka Comapny Information
7.18.2 Otsuka Business Overview
7.18.3 Otsuka Anti-tumor Drug Revenue and Gross Margin (2019-2024)
7.18.4 Otsuka Anti-tumor Drug Product Portfolio
7.18.5 Otsuka Recent Developments
8 NORTH AMERICA
8.1 North America Anti-tumor Drug Revenue (2019-2030)
8.2 North America Anti-tumor Drug Revenue by Type (2019-2030)
8.2.1 North America Anti-tumor Drug Revenue by Type (2019-2024)
8.2.2 North America Anti-tumor Drug Revenue by Type (2025-2030)
8.3 North America Anti-tumor Drug Revenue Share by Type (2019-2030)
8.4 North America Anti-tumor Drug Revenue by Application (2019-2030)
8.4.1 North America Anti-tumor Drug Revenue by Application (2019-2024)
8.4.2 North America Anti-tumor Drug Revenue by Application (2025-2030)
8.5 North America Anti-tumor Drug Revenue Share by Application (2019-2030)
8.6 North America Anti-tumor Drug Revenue by Country
8.6.1 North America Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Anti-tumor Drug Revenue by Country (2019-2024)
8.6.3 North America Anti-tumor Drug Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Anti-tumor Drug Revenue (2019-2030)
9.2 Europe Anti-tumor Drug Revenue by Type (2019-2030)
9.2.1 Europe Anti-tumor Drug Revenue by Type (2019-2024)
9.2.2 Europe Anti-tumor Drug Revenue by Type (2025-2030)
9.3 Europe Anti-tumor Drug Revenue Share by Type (2019-2030)
9.4 Europe Anti-tumor Drug Revenue by Application (2019-2030)
9.4.1 Europe Anti-tumor Drug Revenue by Application (2019-2024)
9.4.2 Europe Anti-tumor Drug Revenue by Application (2025-2030)
9.5 Europe Anti-tumor Drug Revenue Share by Application (2019-2030)
9.6 Europe Anti-tumor Drug Revenue by Country
9.6.1 Europe Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Anti-tumor Drug Revenue by Country (2019-2024)
9.6.3 Europe Anti-tumor Drug Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Anti-tumor Drug Revenue (2019-2030)
10.2 China Anti-tumor Drug Revenue by Type (2019-2030)
10.2.1 China Anti-tumor Drug Revenue by Type (2019-2024)
10.2.2 China Anti-tumor Drug Revenue by Type (2025-2030)
10.3 China Anti-tumor Drug Revenue Share by Type (2019-2030)
10.4 China Anti-tumor Drug Revenue by Application (2019-2030)
10.4.1 China Anti-tumor Drug Revenue by Application (2019-2024)
10.4.2 China Anti-tumor Drug Revenue by Application (2025-2030)
10.5 China Anti-tumor Drug Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Anti-tumor Drug Revenue (2019-2030)
11.2 Asia Anti-tumor Drug Revenue by Type (2019-2030)
11.2.1 Asia Anti-tumor Drug Revenue by Type (2019-2024)
11.2.2 Asia Anti-tumor Drug Revenue by Type (2025-2030)
11.3 Asia Anti-tumor Drug Revenue Share by Type (2019-2030)
11.4 Asia Anti-tumor Drug Revenue by Application (2019-2030)
11.4.1 Asia Anti-tumor Drug Revenue by Application (2019-2024)
11.4.2 Asia Anti-tumor Drug Revenue by Application (2025-2030)
11.5 Asia Anti-tumor Drug Revenue Share by Application (2019-2030)
11.6 Asia Anti-tumor Drug Revenue by Country
11.6.1 Asia Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Anti-tumor Drug Revenue by Country (2019-2024)
11.6.3 Asia Anti-tumor Drug Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Anti-tumor Drug Revenue (2019-2030)
12.2 MEALA Anti-tumor Drug Revenue by Type (2019-2030)
12.2.1 MEALA Anti-tumor Drug Revenue by Type (2019-2024)
12.2.2 MEALA Anti-tumor Drug Revenue by Type (2025-2030)
12.3 MEALA Anti-tumor Drug Revenue Share by Type (2019-2030)
12.4 MEALA Anti-tumor Drug Revenue by Application (2019-2030)
12.4.1 MEALA Anti-tumor Drug Revenue by Application (2019-2024)
12.4.2 MEALA Anti-tumor Drug Revenue by Application (2025-2030)
12.5 MEALA Anti-tumor Drug Revenue Share by Application (2019-2030)
12.6 MEALA Anti-tumor Drug Revenue by Country
12.6.1 MEALA Anti-tumor Drug Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Anti-tumor Drug Revenue by Country (2019-2024)
12.6.3 MEALA Anti-tumor Drug Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
